Stem definition | Drug id | CAS RN |
---|---|---|
serotonin receptor antagonists (5-HT3) | 1992 | 99614-02-5 |
Dose | Unit | Route |
---|---|---|
16 | mg | O |
16 | mg | P |
16 | mg | R |
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 62 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
CL (Clearance) | 5.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 32 mg/mL | Bocci G, Oprea TI, Benet LZ |
t_half (Half-life) | 3.40 hours | Lombardo F, Berellini G, Obach RS |
Vd (Volume of distribution) | 1.80 L/kg | Lombardo F, Berellini G, Obach RS |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.17 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
fu (Fraction unbound in plasma) | 0.27 % | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 25, 2022 | PMDA | Maruishi Pharmaceutical Co., Ltd | |
Jan. 4, 1991 | FDA | NOVARTIS PHARMS CORP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 1194.84 | 10.17 | 1782 | 227116 | 116667 | 63143457 |
Drug ineffective | 976.58 | 10.17 | 1417 | 227481 | 1043348 | 62216776 |
Nausea | 707.48 | 10.17 | 5372 | 223526 | 849099 | 62411025 |
Vomiting | 612.53 | 10.17 | 3772 | 225126 | 555845 | 62704279 |
Synovitis | 602.77 | 10.17 | 15 | 228883 | 186903 | 63073221 |
Systemic lupus erythematosus | 550.14 | 10.17 | 57 | 228841 | 208861 | 63051263 |
Hand deformity | 529.18 | 10.17 | 9 | 228889 | 159448 | 63100676 |
Constipation | 522.63 | 10.17 | 1890 | 227008 | 223053 | 63037071 |
Arthropathy | 509.15 | 10.17 | 112 | 228786 | 234680 | 63025444 |
Contraindicated product administered | 494.40 | 10.17 | 93 | 228805 | 217555 | 63042569 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 932.41 | 10.64 | 1753 | 127999 | 135096 | 34692083 |
Vomiting | 463.03 | 10.64 | 1980 | 127772 | 245641 | 34581538 |
Drug ineffective | 368.54 | 10.64 | 713 | 129039 | 456038 | 34371141 |
Nausea | 315.34 | 10.64 | 2247 | 127505 | 337661 | 34489518 |
Drug abuse | 260.58 | 10.64 | 31 | 129721 | 99065 | 34728114 |
Completed suicide | 252.55 | 10.64 | 33 | 129719 | 98135 | 34729044 |
Toxicity to various agents | 218.83 | 10.64 | 253 | 129499 | 200109 | 34627070 |
Constipation | 178.36 | 10.64 | 989 | 128763 | 135993 | 34691186 |
Cytokine release syndrome | 173.95 | 10.64 | 308 | 129444 | 22569 | 34804610 |
Serotonin syndrome | 173.51 | 10.64 | 285 | 129467 | 19648 | 34807531 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 2078.44 | 9.98 | 3326 | 289366 | 227673 | 79224023 |
Drug ineffective | 919.51 | 9.98 | 1605 | 291087 | 1079308 | 78372388 |
Vomiting | 901.86 | 9.98 | 4812 | 287880 | 661016 | 78790680 |
Nausea | 776.53 | 9.98 | 6075 | 286617 | 951121 | 78500575 |
Constipation | 494.13 | 9.98 | 2203 | 290489 | 280847 | 79170849 |
Synovitis | 470.68 | 9.98 | 19 | 292673 | 150715 | 79300981 |
Neutropenia | 452.49 | 9.98 | 2172 | 290520 | 285538 | 79166158 |
Drug abuse | 444.18 | 9.98 | 42 | 292650 | 162649 | 79289047 |
Diarrhoea | 413.07 | 9.98 | 4986 | 287706 | 875503 | 78576193 |
Serotonin syndrome | 384.05 | 9.98 | 634 | 292058 | 44393 | 79407303 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Human herpesvirus 6 infection | 47.75 | 35.52 | 15 | 340 | 45 | 89392 |
Cardiac failure | 45.06 | 35.52 | 15 | 340 | 57 | 89380 |
Congestive cardiomyopathy | 41.28 | 35.52 | 14 | 341 | 57 | 89380 |
Multiple organ dysfunction syndrome | 36.76 | 35.52 | 15 | 340 | 112 | 89325 |
Source | Code | Description |
---|---|---|
ATC | A04AA01 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Serotonin (5HT3) antagonists |
FDA EPC | N0000175818 | Serotonin-3 Receptor Antagonist |
FDA MoA | N0000175817 | Serotonin 3 Receptor Antagonists |
MeSH PA | D000932 | Antiemetics |
MeSH PA | D000982 | Antipruritics |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chemotherapy-induced nausea and vomiting | indication | 236084000 | |
Prevention of Radiation-Induced Nausea and Vomiting | indication | ||
Prevention of Post-Operative Nausea and Vomiting | indication | ||
Excessive vomiting in pregnancy | off-label use | 14094001 | |
Torsades de pointes | contraindication | 31722008 | |
Hepatic failure | contraindication | 59927004 | |
Extrapyramidal disease | contraindication | 76349003 | |
Prolonged QT interval | contraindication | 111975006 | |
Seizure disorder | contraindication | 128613002 | |
Congenital long QT syndrome | contraindication | 442917000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.13 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 7.80 | WOMBAT-PK | CHEMBL | |||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.34 | DRUG MATRIX | |||||
Aldehyde oxidase | Enzyme | IC50 | 5.68 | WOMBAT-PK | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.69 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 5.77 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 7.52 | CHEMBL | |||||
Multidrug and toxin extrusion protein 2 | Transporter | IC50 | 6.80 | CHEMBL | |||||
Solute carrier family 22 member 3 | Transporter | IC50 | 4.76 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 4.34 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.09 | WOMBAT-PK |
ID | Source |
---|---|
S87 | PDB_CHEM_ID |
003568 | NDDF |
004807 | NDDF |
103639-04-9 | SECONDARY_CAS_RN |
108418007 | SNOMEDCT_US |
108419004 | SNOMEDCT_US |
203148 | RXNORM |
2290 | IUPHAR_LIGAND_ID |
27290 | MMSL |
372487007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9890 | INJECTION | 2 mg | INTRAMUSCULAR | ANDA | 26 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9891 | INJECTION | 2 mg | INTRAMUSCULAR | ANDA | 26 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0315 | TABLET, FILM COATED | 4 mg | ORAL | ANDA | 28 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0344 | TABLET, FILM COATED | 8 mg | ORAL | ANDA | 28 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0374 | TABLET, FILM COATED | 24 mg | ORAL | ANDA | 28 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7732 | TABLET, ORALLY DISINTEGRATING | 4 mg | ORAL | ANDA | 28 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7734 | TABLET, ORALLY DISINTEGRATING | 8 mg | ORAL | ANDA | 28 sections |
ONDANSETRON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9930 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 19 sections |
ONDANSETRON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9930 | INJECTION | 2 mg | INTRAVENOUS | ANDA | 19 sections |
Ondansetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0409-4755 | INJECTION, SOLUTION | 2 mg | INTRAMUSCULAR | ANDA | 32 sections |